Supplementation with cholecalciferol during pregnancy linked to increased bone mineral content, bone mineral density, lean mass in offspring ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

Source: Getty Images “The potential adverse impact of chemotherapy exposure during pregnancy is likely mediated through ...

Researchers analyzed whole-genome sequencing data from 76,805 patients to identify variants in 4 genes that are associated ...

The Food and Drug Administration (FDA) has expanded the approval of Nerivio ® (Theranica) to include the acute and/or ...

One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.